

PATENT APPLICATION
JC10 Rec'd PCT/PTO 05 MAY 2005
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Piero DEL SOLDATO, et al.

Group Art Unit: Unknown

Examiner: Unknown

Application No.: 10/523,722 (Unofficial)

Atty. Dkt. No.: 026220-00062

Filed: February 7, 2005

For: PROCESS FOR PREPARING NITROOXYDERIVATIVES OF NAPROXEN

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

May 5, 2005


Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached Form PTO-SB08. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date or the date of filing a CPA, OR (b) before the mailing date of a first Office Action on the merits in the present application, or (c) accompanies a Request for Continued Examination. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

- ☐ c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$130.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

Respectfully submitted,


Richard J. Berman
Registration No. 39,107

Customer No. 004372
Arent Fox PLLC
1050 Connecticut Avenue, N.W., Suite 400
Washington, D.C. 20036-5339
Tel: (202) 857-6000
Fax: (202) 638-4810

RJB:mso

Enclosures: Form PTO-SB08; Search Report; References (8)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO/SB/08a

Application Number	10/523,722 (Unofficial)
Filing Date	February 7, 2005
First Named Inventor	Piero DEL SOLDATO, et al.
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	026220-00062

Sheet	1	of	1
-------	---	----	---

[illegible][illegible]

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO/SB/08b				Complete if Known	
				Application Number	10/523,722 (Unofficial)
				Filing Date	February 7, 2005
				First Named Inventor	Piero DEL SOLDATO, et al.
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	1	of	1	Attorney Docket Number	026220-00062

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
		Yutaka KAWASHIMA, et al.; "Synthesis and Pharmacological Evaluation of (Nitrooxy) alkyl Apovincaminates"; J. Med. Chem, 1993, Volume 36, No. 7, Pages 815-819	XX	
		Toshihisa OGAWA, et al.; "Synthesis and Antihypertensive Activities of New 1,4-Dihydropyridine Derivatives Containing Nitrooxyalkylester Moieties at the 3- and 5-Positions"; Chem. Pharm. Bull. 1993, Vol. 41, No. 6, Pages 1049-1054	XX	
		Claudio GIORDANO, et al.; "A Stereoconvergent Strategy For the Synthesis of Enantiomerically Pure (R)-(-) and (S)-(+)-2-(6-Methoxy-2-Naphthyl)-Propanoic Acid (Naproxen); 1989, Vol. 45, No. 13, Pages 4243-4252	XX	
		Ashraf H. ABADI, et al.; "Synthesis and Cyclooxygenase Inhibitory Properties of Novel (+) 2-(6-Methoxy-2-naphthyl)propanoic Acid (Naproxene) Derivatives" 2001, Pages 104-106	XX	
		Kawaken Fine Chem. Co., Ltd.; "Derwent Publications Ltd.; Section Ch, Week 199347, 10/26/1993	XX	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.